09 February 2024
09 February 2024
This initiative builds on the original parallel scientific advice programme launched by the FDA and and the EMA in 2021.
Despite a $3.73m decline in the sales of Covid-19 medicines, the company's total revenue for 2023 grew by 6%.
The submission is based on data from the Phase III MARIPOSA clinical trial.
The companies will utilise translational medicine approaches to expedite the development of first-in-class medicines.
BioNTech will acquire Autolus’ American depositary shares for $200m in a private placement.
The survey by CRO Worldwide Clinical Trials shows that pharma and biotechs favour midsize contract research organisations (CROs) due to the personalised service.
Kowa will pay €3m upfront and up to €27.5m in milestone-based payment to gain rights for Nicox’s intraocular pressure (IOP) reduction drug in Japan.
AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards a biologics licence application (BLA) from the US Food and Drug Administration (FDA).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
